IRYCIS

Biomarkers toidentify IFN-BETA drug response in multiple sclerosis

Biomarkers / Diagnostic
Autoimmune & Inflammation
Central Nervous System
New patented method to identify good responders to Interferon beta (INF-beta) therapy in multiple sclerosis before treatment initiation
5Ready to Market, 4Register, 3Clinical validation, 2Preclinical Validation, 1R+D
Spain